Full-Time

Head of Patient Care Operations

Ottobock

Ottobock

1,001-5,000 employees

Provider of prosthetics, orthotics, wheelchairs, exoskeletons

No salary listed

Germany

In Person

Category
Operations & Logistics (2)
,

Get referred to Ottobock

See people who can refer or advise you

Requirements
  • Master's degree in specialist studies
  • At least 8 years of experience in managing a medical device manufacturing facility
  • Extensive experience in setting up and operating a centralized production structure
  • In-depth knowledge of production processes and tools for batch size 1 products
  • Strategic and far-sighted mindset with persuasive and assertive skills
  • Numerate with an affinity for key figures
  • Excellent German and English language skills
Responsibilities
  • You will capture the status quo of global patient care production (available production resources, tools, processes, etc.)
  • You will identify, among other things, best-in-class processes, tools and cost advantages per manufacturing step/product type
  • You will distinguish processes, products and solutions to be moved to a centralized manufacturing facility
  • You will develop a centralized manufacturing strategy or footprint (short/medium/long term)
  • You will build and extend an integrated production and process chain - including the required systems/tools such as ordering and communication platform
  • You will transfer the local and heterogeneous manufacturing processes into an integrated central manufacturing process chain
  • You will have the technical leadership of the local units in all topics related to production processes and tools (harmonization/standardization of the remaining local processes and tools to a global standard according to the cfab strategy)
  • You will work with international development project teams to ensure a seamless production launch of new products

Ottobock is a global producer of orthopedic technology, focusing on prosthetics, orthotics, wheelchairs, and exoskeletons. Its products range from basic devices to advanced, microprocessor-controlled prosthetics and ergonomic exoskeletons that help people move more easily and stay independent. These devices work by using sensors, motors, and smart controls to adapt to a user’s movement, pace, and terrain, providing ankle and knee assistance or full upper- and lower-limb support. compared with others, Ottobock stands out as a family-owned company with a long history, a broad international footprint in about 60 countries, a large workforce, and a strong commitment to social responsibility, including a long-running partnership with the Paralympic Games. Its core goal is to improve mobility and quality of life for people with disabilities by delivering reliable, high-quality mobility solutions.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Duderstadt, Germany

Founded

1919

Get referred to Ottobock

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FES acquisition from Fesia expands neuro-orthotics portfolio for rising neurological condition patients worldwide.
  • RESTORE™ System investment enables intuitive prosthetic control, boosting market demand for high-end prosthetics.
  • Global 400-center network delivers integrated clinical and tech services, strengthening patient loyalty and market share.

What critics are saying

  • FTC-mandated divestiture of Freedom Innovations assets likely in 6–12 months, causing critical market share loss to Freedom as direct competitor.
  • Ossur capturing 15% of European prosthetics market by 2027 erodes premium pricing amid intensified competition from Ossur and Willow.
  • Unapproved FDA FES classification from Fesia acquisition may trigger $50M+ recall and 9-month neuro-orthotics revenue delay in 9–12 months.

What makes Ottobock unique

  • Ottobock acquires Fesia Technology to expand neuro-orthotics with FES systems for stroke and spinal injury patients.
  • Invests $5M in Blue Arbor to advance RESTORE™ System enabling direct neuromuscular control of prosthetics with five-year stability.
  • Holds 2,110 patents and operates 400 care centers globally, leading in prosthetics, neuro-orthotics, and exoskeletons with sensor-integrated tech.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

401(k) Company Match

100% company-paid short & long-term disability

Company News

Morningstar
Feb 26th, 2026
Blue Arbor secures $5M from Ottobock to advance FDA breakthrough prosthetic control system

Blue Arbor Technologies has secured a $5 million investment from Ottobock, the global prosthetics leader, to advance its RESTORE Neuromuscular Interface System. Ottobock will lead Blue Arbor's Series A financing and hold a board seat. The FDA breakthrough-designated RESTORE System provides a fully implanted neuromuscular interface connecting advanced prostheses directly to patients' residual muscles and peripheral nerves. It enables independent, simultaneous control of fingers, wrist and elbow, with trials demonstrating stable signal capture for over five years. In December 2025, surgeons at the Medical University of Vienna completed the first-in-human RESTORE procedure. Within days, the patient demonstrated functional use with an Ottobock prosthetic. Founded by Drs Paul Cederna, Theodore Kung and Alex Vaskov, Blue Arbor has been awarded over $60 million in research grants and published more than 200 peer-reviewed papers.

Business Wire
Feb 26th, 2026
Blue Arbor Technologies Announces Strategic Partnership with Ottobock and $5 Million Investment to Advance RESTORE™ Neuromuscular Interface System

Blue Arbor Technologies announces $5 million investment by Ottobock to advance RESTORE™ System, designed to enable intuitive prosthetic control

De Tijd
Oct 24th, 2025
Onward Raises €50.85M from Investors

Onward has completed its capital round, securing €50.85 million from a group of major investors.

Investing.com
Oct 17th, 2025
Ottobock IPO Shares Stabilize at €66

Ottobock SE & Co. KGaA shares have been stabilizing since their IPO on October 14, with trading starting at €66.00. The lowest price reached was €64.50 on October 17. Stabilization measures, managed by Goldman Sachs Bank Europe SE, have been conducted daily across multiple trading venues, including XETRA and the Frankfurt Stock Exchange. The base offering included 10,640,151 shares. The shares are trading under ISIN DE000BCK2223.

Bloomberg L.P.
Oct 9th, 2025
Ottobock Shares Rise After Biggest German IPO of 2025

Ottobock SE & Co. shares rose in the prosthetics firm’s debut trading session in Frankfurt on Thursday, after the biggest initial public offering in Germany in more than a year.